Humoral responses to the measles, mumps and rubella vaccine are impaired in Leigh Syndrome French Canadian patients
Fiche du document
17 janvier 2023
- handle: 10670/1.7s6j81
- doi: 10.1371/journal.pone.0239860
Ce document est mis à disposition selon les termes de la Licence Creative Commons Paternité 4.0 International. / This work is licensed under a Creative Commons Attribution 4.0 International License. , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Rubeola notha Three-day measles Fourth disease Röteln Rosella Measles, German German measles Epidemic parotitis Rubeola Morbilli Immune globulins Antibodies Immune serum globulin Frenchmen (French people)Citer ce document
Adrien Fois et al., « Humoral responses to the measles, mumps and rubella vaccine are impaired in Leigh Syndrome French Canadian patients », Papyrus : le dépôt institutionnel de l'Université de Montréal, ID : 10.1371/journal.pone.0239860
Métriques
Partage / Export
Résumé
Leigh Syndrome French Canadian (LSFC) is a rare autosomal recessive metabolic disorder characterized by severe lactic acidosis crises and early mortality. LSFC patients carry mutations in the Leucine Rich Pentatricopeptide Repeat Containing (LRPPRC) gene, which lead to defects in the respiratory chain complexes and mitochondrial dysfunction. Mitochondrial respiration modulates cellular metabolic activity, which impacts many cell types including the differentiation and function of immune cells. Hence, we postulated that, in addition to neurological and metabolic disorders, LSFC patients may show impaired immune activity. To gain insight into the quality of the immune response in LSFC patients, we examined the response to the measles, mumps and rubella (MMR) vaccine by measuring antibody titers to MMR in the plasma. In a cohort of eight LSFC patients, the response to the MMR vaccine was variable, with some individuals showing antibodies to all three viruses, while others had antibodies to two or fewer viruses. These results suggest that the mutations in the LRPPRC gene present in LSFC patients may affect the immune response to vaccines. Monitoring vaccine response in this fragile population should be considered to ensure full protection against pathogens.